论文部分内容阅读
目的探讨白三烯受体拮抗剂孟鲁司特钠治疗儿童咳嗽变异性哮喘的疗效。方法选择2014年1—6月收治的60例咳嗽变异性哮喘患儿作为研究对象,随机分成对照组和观察组各30例。对照组给予丙酸倍氯米松吸入治疗,100μg/次,2次/d;观察组在对照组的基础上加用白三烯受体拮抗剂孟鲁司特钠治疗,3~5岁患儿4 mg/次,1次/d,6~14岁患儿5 mg/次,1次/d,睡前服用。两组均治疗3个月。比较两组治疗效果及复发情况。计量资料采用t检验,计数资料采用χ2检验,P<0.05为差异有统计学意义。结果观察组总有效率为96.67%,高于对照组的56.67%,差异有统计学意义(P<0.05)。观察组哮喘持续时间、咳嗽消失时间、肺部哮鸣音消失时间分别为(3.59±1.42)、(6.51±0.39)、(3.40±0.33)d,对照组分别为(7.51±1.43)、(10.77±1.20)、(8.79±1.62)d,两组比较差异均有统计学意义(均P<0.05)。结论白三烯受体拮抗剂孟鲁司特钠治疗儿童咳嗽变异性哮喘效果明显,治疗后不易复发,值得临床推广应用。
Objective To investigate the efficacy of montelukast sodium antagonist leukotriene receptor antagonist in children with cough variant asthma. Methods Sixty children with cough variant asthma admitted from January to June in 2014 were randomly divided into control group and observation group with 30 cases each. The control group was given beclomethasone propionate inhalation treatment, 100μg / time, 2 times / d; the observation group in the control group based on the addition of leukotriene receptor antagonist montelukast sodium treatment, 3 to 5-year-old children 4 mg / time, 1 time / d, 6 to 14-year-old children 5 mg / time, 1 time / d, taken before bedtime. Both groups were treated for 3 months. The therapeutic effect and recurrence of the two groups were compared. Measurement data using t test, count data using χ2 test, P <0.05 for the difference was statistically significant. Results The total effective rate in observation group was 96.67%, which was higher than that in control group (56.67%), the difference was statistically significant (P <0.05). The duration of asthma, the disappearance of cough and the disappearance time of lung wheeze in the observation group were (3.59 ± 1.42) and (6.51 ± 0.39) days and (3.40 ± 0.33) days respectively, and those in the control group were 7.51 ± 1.43 and 10.77 ± 1.20) and (8.79 ± 1.62) d, respectively, with significant differences between the two groups (all P <0.05). Conclusion The leukotriene receptor antagonist montelukast sodium is effective in treating children with cough variant asthma. It is difficult to relapse after treatment and is worthy of clinical application.